Quratulain Shabbir, MD
Nephrology · Hot Springs, ARNPI 1457663155
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for nephrology clinicians in AR, where the typical reported total is $925.
Across 33 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ardelyx, Inc.$132
- AstraZeneca$89
- Otsuka America Pharmaceutical, Inc.$84
- Amgen$70
- Vifor Pharma, Inc.$67
- Akebia Therapeutics Inc$51
- plus $126 from 5 others
What the payments were for
- Food & beverage$619100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ardelyx, Inc. | 6 | $132 |
| AstraZeneca | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Amgen | 3 | $70 |
| Vifor Pharma, Inc. | 4 | $67 |
| Akebia Therapeutics Inc | 2 | $51 |
| GSK | 3 | $49 |
| Travere Therapeutics, Inc. | 3 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Calliditas Therapeutics US Inc. | 1 | $18 |
| Aurinia Pharma U.S., Inc. | 1 | $12 |
How this compares
$619 in reported general payments places this provider in the 45th percentile of 85 nephrology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Calcitriol | 64 | $939 |
| Bumetanide | 26 | $552 |
| Lisinopril | 43 | $409 |
| Losartan Potassium | 56 | $242 |
| Omeprazole | 14 | $205 |
| Carvedilol | 44 | $188 |
| Nifedipine ErNifedipine | 14 | $187 |
| Spironolactone | 19 | $172 |
| Levothyroxine Sodium | 18 | $160 |
| Midodrine Hcl | 13 | $120 |
| Furosemide | 38 | $89 |
| Atorvastatin Calcium | 11 | $83 |
| Pantoprazole Sodium | 11 | $74 |
| Amlodipine Besylate | 27 | $69 |
| Benazepril Hcl | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Hot Springs
- Michael GerschHot Springs$10K
- Donna McGheeHot Springs$4K
- David DesotoHot Springs$3K
- Naveen TrehanHot Springs$2K
- Robert McCraryHot Springs$631
- John SmithHot Springs$298
- Drew HeipleRussellville$236K
- Luis JuncosLittle Rock$66K
- John HeifnerLittle Rock$45K
- Shaker QaqishNorth Little Rock$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.